Federal contract award
75N91025C00039
NOVEL THERANOSTIC RADIOLIGANDS TARGETING DISEASE-SPECIFIC EXTRACELLULAR MATRIX COMPONENTS SPECIFIC TO TUMOR AND METASTATIC LESIONS IN PATIENTS SUFFERING FROM HEREDITARY BREAST AND OVARIAN CANCER (HBOC)
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | SMALL BUSINESS SET ASIDE - TOTAL |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $299.5K |
| Current contract value | $299.5K |
| Potential contract value / ceiling | $299.5K |
| Start date | Sep 15, 2025 |
| Current end date | Sep 14, 2026 |
| Potential end date | Sep 14, 2026 |
| Latest award activity | Sep 10, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 10, 2026 | P00001 | $-55.0K | NOVEL THERANOSTIC RADIOLIGANDS TARGETING DISEASE-SPECIFIC EXTRACELLULAR MATRIX COMPONENTS SPECIFIC TO TUMOR AND METASTATIC LESIONS IN PATIENTS SUFFERING FROM HEREDITARY BREAST AND OVARIAN CANCER (HBOC) |
| Sep 11, 2025 | 0 | $354.5K | NOVEL THERANOSTIC RADIOLIGANDS TARGETING DISEASE-SPECIFIC EXTRACELLULAR MATRIX COMPONENTS SPECIFIC TO TUMOR AND METASTATIC LESIONS IN PATIENTS SUFFERING FROM HEREDITARY BREAST AND OVARIAN CANCER (HBOC) |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.